Document Type

Article

Publication Date

11-1-2014

Comments

This article has been peer reviewed. It is the author’s final published version in Clinical Cancer Research Volume 20, Issue 21, November 2014, Pages 5343-5345.

The published version is available at DOI: 10.1158/1078-0432.CCR-14-1188. Copyright © American Association for Cancer Research

Abstract

One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production. New evidence points toward androstenedione as a potential precursor of intratumor androgen production and furthers nomination of AKR1C3 as a therapeutic target in advanced disease. Clin Cancer Res; 20(21); 5343-5. ©2014 AACR.

Share

COinS